Literature DB >> 11128348

Reduced insulin secretion in offspring of African type 2 diabetic parents.

J C Mbanya1, L N Pani, D N Mbanya, E Sobngwi, J Ngogang.   

Abstract

OBJECTIVE: To determine the early biochemical predictors of increased susceptibility to develop diabetes in offspring of African type 2 diabetic parents. RESEARCH DESIGN AND METHODS: A total of 69 offspring (case subjects) of 26 families in Cameroon with at least one type 2 diabetic parent were studied, and 62 offspring (control subjects) from 25 families in Cameroon with no parent with type 2 diabetes underwent an oral glucose tolerance test. Early insulin secretion was calculated using the ratio of the 0- to 30-min incremental insulin values to the 0- to 30-min incremental glucose. Anthropometric parameters were also measured.
RESULTS: Of the case subjects, 23% were glucose intolerant (4% with diabetes and 19% with impaired glucose tolerance [IGT]) compared with 6.5% (all with IGT) of control subjects (P = 0.02). There was also an increasing prevalence of glucose intolerance, especially IGT with increasing number of glucose-intolerant parents. Fasting serum insulin levels were not different in the two groups; however, at 30 min, the case subjects had lower insulin levels than the control subjects (P < 0.006). Case subjects with IGT had lower 30-min insulin concentration, early insulin secretion, and 2-h insulin levels than those with normal glucose tolerance (NGT) (F = 4.1, P < 0.05; F = 4.1, P < 0.04; and F = 5.1, P < 0.03, respectively). Furthermore, case subjects with NGT and IGT had lower early insulin secretion than control subjects (F = 4. 1, P < 0.03). These differences remained after adjustment for BMI and regardless of the status of parental diabetes. Two-hour insulin concentration showed a positive association (odds ratio = 0.95 CI 0.90-0.99, P = 0.039) with IGT in the case subjects.
CONCLUSIONS: Diabetes and IGT are more prevalent in the offspring of African type 2 diabetic parents, and this may be due to an underlying degree of beta-cell impairment marked by reduced early-phase insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128348     DOI: 10.2337/diacare.23.12.1761

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Parental History of Type 2 Diabetes Abrogates Ethnic Disparities in Key Glucoregulatory Indices.

Authors:  Ebenezer Nyenwe; Ibiye Owei; Jim Wan; Sam Dagogo-Jack
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

2.  Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): design and methods.

Authors:  Samuel Dagogo-Jack; Chimaroke Edeoga; Ebenezer Nyenwe; Emmanuel Chapp-Jumbo; Jim Wan
Journal:  Ethn Dis       Date:  2011       Impact factor: 1.847

Review 3.  Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities.

Authors:  Ayesha A Motala; Jean Claude Mbanya; Kaushik Ramaiya; Fraser J Pirie; Kenneth Ekoru
Journal:  Nat Rev Endocrinol       Date:  2022-01-04       Impact factor: 47.564

Review 4.  Genetic epidemiology of type 2 diabetes and cardiovascular diseases in Africa.

Authors:  Fasil Tekola-Ayele; Adebowale A Adeyemo; Charles N Rotimi
Journal:  Prog Cardiovasc Dis       Date:  2013 Nov-Dec       Impact factor: 8.194

Review 5.  Stroke genomics in people of African ancestry: charting new paths.

Authors:  R O Akinyemi; B Ovbiagele; A Akpalu; C Jenkins; K Sagoe; L Owolabi; F Sarfo; R Obiako; M Gebreziabher; E Melikam; S Warth; O Arulogun; D Lackland; A Ogunniyi; H Tiwari; R N Kalaria; D Arnett; M O Owolabi
Journal:  Cardiovasc J Afr       Date:  2015 Mar-Apr       Impact factor: 1.167

6.  Heritability and Genetics of Type 2 Diabetes Mellitus in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.

Authors:  Evans Adu Asamoah; Christian Obirikorang; Emmanuel Acheampong; Max Efui Annani-Akollor; Edwin Ferguson Laing; Eddie-Williams Owiredu; Enoch Odame Anto
Journal:  J Diabetes Res       Date:  2020-06-30       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.